| 引用本文: | 董超,马萱,史延茂.血栓病治疗药物-纤溶酶的生物来源[J].生物信息学,2019,17(2):76-85. |
| DONG Chao,MA Xuan,SHI Yanmao.Thrombolytic drugs: Fibrinolytic enzyme and the biological source[J].Chinese Journal of Bioinformatics,2019,17(2):76-85. |
|
| 摘要: |
| 血栓病的干预方式包括抗血小板凝集、抗凝血和溶栓,对应临床应用的分别是抗血小板、抗凝血酶和纤溶酶溶栓药物；纤溶酶是主要的溶栓类药物,主要用于血栓发病后的治疗。纤溶酶种类多来自于生物体,更多来自于微生物的次级代谢。本文从作用方式、安全性和市场开发等方面总结了国内外纤溶酶的类别、研究现状和发展趋势,并对不同产纤溶酶的微生物菌株类别进行了总结,对不同来源的纤溶酶基因和氨基酸序列等信息进行了比较,发现不同物种的纤溶酶基因虽然有差异,但主要是丝氨酸蛋白酶类,氨基酸序列一致性比较高,说明丝氨酸蛋白酶活性功能区域是相对保守的。 |
| 关键词: 血栓病 纤溶酶 微生物种类 |
| DOI：10.12113/j.issn.1672-5565.201810003 |
| 分类号:Q55 |
| 文献标识码:A |
| 基金项目:河北省科学院科技项目(No.19308). |
|
| Thrombolytic drugs: Fibrinolytic enzyme and the biological source |
|
DONG Chao, MA Xuan, SHI Yanmao
|
|
(Biology Institute, Hebei Academy of Sciences, Shijiazhuang 050081, China)
|
| Abstract: |
| For thrombus, the medical interventions consist of antiplatelet agglutination, antiaggregation, and thrombolysis. The corresponding drugs are antiplatelet, antithrombin, and fibrinolytic enzyme. As the main medical drug for diseased thrombus, most of fibrinolytic enzyme comes from organisms such as secondary metabolism of microbial. This paper discusses the classification, research status, and developing trends of fibrinolytic enzyme at home and abroad from the perspectives of type of action, safety, and tap potential. The strains of microorganism producing fibrinolytic enzyme are summarized. The comparison results show that the fibrinolytic enzyme gene sequence was different for different species, but the expression of protein-amino acid sequence was more consistent. It also proved that protein functional region of the serine protease is conservative. |
| Key words: Thrombus Fibrinolytic enzyme Microorganism |
